HRP20130057T1 - Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom - Google Patents
Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom Download PDFInfo
- Publication number
- HRP20130057T1 HRP20130057T1 HRP20130057AT HRP20130057T HRP20130057T1 HR P20130057 T1 HRP20130057 T1 HR P20130057T1 HR P20130057A T HRP20130057A T HR P20130057AT HR P20130057 T HRP20130057 T HR P20130057T HR P20130057 T1 HRP20130057 T1 HR P20130057T1
- Authority
- HR
- Croatia
- Prior art keywords
- ibudilast
- pharmaceutically acceptable
- acceptable salt
- day
- intended
- Prior art date
Links
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 title claims 11
- 229960002491 ibudilast Drugs 0.000 title claims 11
- 230000004770 neurodegeneration Effects 0.000 title claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 title claims 3
- 230000000750 progressive effect Effects 0.000 title claims 2
- 150000003839 salts Chemical class 0.000 claims 10
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (6)
1. Ibudilast, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku ublažavanja negativnih posljedica progresivne neurodegenerativne bolesti kod ljudskog pacijenta, gdje pacijent boluje od primarne progresivne ili sekundarne progresivne multiple skleroze.
2. Ibudilast, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je pacijentova neurodegenerativna bolest napredovala dalje od povratne, remitirajuće multiple skleroze.
3. Ibudilast, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se postupak sastoji u primjeni ibudilasta, ili njegove farmaceutski prihvatljive soli, pet puta dnevno, četiri puta dnevno, tri puta dnevno, dva puta dnevno, svaki drugi dan, tri puta tjedno, dva puta tjedno, jednom tjedno, dva puta mjesečno ili jednom mjesečno.
4. Ibudilast, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak sastoji u oralnoj primjeni ibudilasta, ili njegove farmaceutski prihvatljive soli.
5. Ibudilast, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak sastoji u primjeni ibudilasta, ili njegove farmaceutski prihvatljive soli, u količini od 30 mg do 240 mg dnevno.
6. Ibudilast, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak sastoji u primjeni ibudilasta, ili njegove farmaceutski prihvatljive soli, u trajanju od 1-2 godine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92974507P | 2007-07-11 | 2007-07-11 | |
| US4218108P | 2008-04-03 | 2008-04-03 | |
| PCT/US2008/069417 WO2009009529A1 (en) | 2007-07-11 | 2008-07-08 | Treatment of progressive neurodegenerative disease with ibudilast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130057T1 true HRP20130057T1 (hr) | 2013-02-28 |
Family
ID=39789775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130057AT HRP20130057T1 (hr) | 2007-07-11 | 2013-01-23 | Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US8138201B2 (hr) |
| EP (2) | EP2187882B1 (hr) |
| JP (2) | JP5468001B2 (hr) |
| CN (1) | CN101848712B (hr) |
| AU (1) | AU2008275148A1 (hr) |
| BR (1) | BRPI0814624A2 (hr) |
| CA (2) | CA2693697C (hr) |
| DK (1) | DK2187882T3 (hr) |
| ES (1) | ES2402175T3 (hr) |
| HR (1) | HRP20130057T1 (hr) |
| PL (1) | PL2187882T3 (hr) |
| PT (1) | PT2187882E (hr) |
| TW (1) | TW200918051A (hr) |
| WO (1) | WO2009009529A1 (hr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120037477A (ko) * | 2009-06-19 | 2012-04-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 다발경화증의 치료 |
| CA2766632A1 (en) | 2009-06-23 | 2010-12-29 | Medicinova, Inc. | Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one and related methods |
| HUE027680T2 (en) * | 2009-07-30 | 2016-11-28 | Teva Pharma | Treatment of Crohn's disease with laquinimod |
| PL3064206T3 (pl) * | 2009-08-10 | 2020-02-28 | Active Biotech Ab | Leczenie choroby Huntingtona z zastosowaniem lakwinimodu |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| JP5916622B2 (ja) * | 2010-01-04 | 2016-05-11 | マピ ファーマ リミテッド | グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム |
| EA201290860A1 (ru) * | 2010-03-03 | 2013-04-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата |
| ES2558556T3 (es) * | 2010-03-03 | 2016-02-05 | Teva Pharmaceutical Industries Ltd. | Tratamiento de nefritis lúpica usando laquinimod |
| SG183515A1 (en) * | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
| ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| CN103255142B (zh) * | 2012-02-21 | 2017-07-25 | 上海转基因研究中心 | 一种利用RNAi调控内源性朊蛋白表达的方法及其应用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| CN103505731A (zh) * | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| FR3000746A1 (fr) | 2013-01-04 | 2014-07-11 | Centre Nat Rech Scient | Peptide pour son utilisation dans le traitement des neuronopathies motrices |
| WO2014127139A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| JP2016517883A (ja) * | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
| EP3137092A4 (en) | 2014-04-29 | 2017-10-11 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| US20150366847A1 (en) * | 2014-06-20 | 2015-12-24 | Medicinova, Inc. | Combination of geranylgeranylacetone and ibudilast and methods of using same |
| WO2016044103A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| WO2016086000A1 (en) * | 2014-11-26 | 2016-06-02 | Medicinova, Inc. | A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same |
| JP6827924B2 (ja) * | 2014-11-26 | 2021-02-10 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラスト及びリルゾールの組み合わせを含む医薬および組成物 |
| CN105395511A (zh) * | 2015-12-07 | 2016-03-16 | 黑龙江省智诚医药科技有限公司 | 一种异丁司特缓释微丸及其制备方法 |
| JP2019514978A (ja) * | 2016-05-10 | 2019-06-06 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラストを使用したアルコール依存症並びにうつ病及び／又は不快な気分の治療 |
| JP2020504721A (ja) | 2016-12-22 | 2020-02-13 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラストを使用した多形膠芽腫の治療方法 |
| MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
| EP3740205B1 (en) * | 2018-02-12 | 2023-09-20 | MediciNova, Inc. | Methods of suppressing myeloid-derived suppressor cells in patients |
| EP3752147A4 (en) * | 2018-02-12 | 2021-10-20 | MediciNova, Inc. | METHODS AND DOSAGE USING IBUDILAST AND A SECOND AGENT FOR CARCINOTHERAPY |
| US10946071B2 (en) * | 2018-10-09 | 2021-03-16 | Medicinova, Inc. | Combination of ibudilast and interferon-beta and methods of using same |
| EP3866788B1 (en) * | 2018-10-19 | 2023-12-13 | MediciNova, Inc. | Treatment of macular injury associated with multiple sclerosis with ibudilast |
| JP2022513449A (ja) | 2018-12-12 | 2022-02-08 | オートバーン セラピューティクス，インク． | 新規な甲状腺模倣物 |
| JP2022524930A (ja) * | 2019-02-26 | 2022-05-11 | ウニベルシタット デ バレンシア―エストゥディ ジェネラル | 運動ニューロン疾患を処置するための方法及び組成物 |
| EP3931180A1 (en) | 2019-03-01 | 2022-01-05 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| WO2020251748A1 (en) * | 2019-06-11 | 2020-12-17 | Yale University | Novel treatment for wolfram syndrome |
| US11865214B2 (en) | 2019-09-23 | 2024-01-09 | Medicinova, Inc. | Ibudilast oral formulations and methods of using same |
| JP2023521030A (ja) | 2020-04-06 | 2023-05-23 | メディシノバ・インコーポレイテッド | イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法 |
| CN116887829A (zh) | 2021-01-29 | 2023-10-13 | 美迪诺亚公司 | 治疗化学气体暴露的方法 |
| CA3226898A1 (en) | 2021-07-26 | 2023-02-02 | Kazuko Matsuda | Ibudilast for preventing eye cancer metastasis |
| CA3231869A1 (en) | 2021-09-21 | 2023-03-30 | Medicinova, Inc. | Ibudilast in combination therapy for use in the treatment of glioblastoma |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
| US20230285367A1 (en) | 2022-02-01 | 2023-09-14 | Medicinova, Inc. | Methods of treating post-covid condition(s) |
| WO2023192885A2 (en) * | 2022-03-28 | 2023-10-05 | Praxis Precision Medicines, Inc. | Methods of using oligomeric compounds to treat scn2a-related disorders |
| US20240016729A1 (en) | 2022-07-13 | 2024-01-18 | Medicinova, Inc. | Injectable formulations of ibudilast |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4828003B2 (ja) | 1998-08-10 | 2011-11-30 | 杏林製薬株式会社 | 多発性硬化症治療薬 |
| JP2004532809A (ja) * | 2000-11-02 | 2004-10-28 | リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク | ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法 |
| US20050043319A1 (en) * | 2001-08-14 | 2005-02-24 | Exonhit Therapeutics Sa | Molecular target of neurotoxicity |
| BRPI0416812A (pt) | 2003-11-21 | 2007-03-06 | Combinatorx Inc | métodos e reagentes para o tratamento de desordens inflamatórias |
| US7534806B2 (en) | 2004-12-06 | 2009-05-19 | Avigen, Inc. | Method for treating neuropathic pain and associated syndromes |
| EP2377530A3 (en) * | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
-
2008
- 2008-07-08 BR BRPI0814624-1A2A patent/BRPI0814624A2/pt not_active Application Discontinuation
- 2008-07-08 AU AU2008275148A patent/AU2008275148A1/en not_active Abandoned
- 2008-07-08 ES ES08781498T patent/ES2402175T3/es active Active
- 2008-07-08 CA CA2693697A patent/CA2693697C/en active Active
- 2008-07-08 JP JP2010516198A patent/JP5468001B2/ja active Active
- 2008-07-08 DK DK08781498.4T patent/DK2187882T3/da active
- 2008-07-08 WO PCT/US2008/069417 patent/WO2009009529A1/en active Application Filing
- 2008-07-08 EP EP08781498A patent/EP2187882B1/en active Active
- 2008-07-08 PL PL08781498T patent/PL2187882T3/pl unknown
- 2008-07-08 CN CN200880106623XA patent/CN101848712B/zh active Active
- 2008-07-08 CA CA2970273A patent/CA2970273C/en active Active
- 2008-07-08 US US12/169,042 patent/US8138201B2/en active Active
- 2008-07-08 EP EP12196108A patent/EP2567699A1/en not_active Withdrawn
- 2008-07-08 PT PT87814984T patent/PT2187882E/pt unknown
- 2008-07-10 TW TW097126065A patent/TW200918051A/zh unknown
-
2012
- 2012-02-22 US US13/402,702 patent/US8338453B2/en active Active
- 2012-12-21 US US13/725,627 patent/US9114136B2/en active Active
-
2013
- 2013-01-23 HR HRP20130057AT patent/HRP20130057T1/hr unknown
- 2013-12-10 JP JP2013255214A patent/JP2014062118A/ja active Pending
-
2014
- 2014-02-24 US US14/188,061 patent/US9314452B2/en active Active
- 2014-09-19 US US14/491,939 patent/US20150011581A1/en not_active Abandoned
-
2016
- 2016-03-23 US US15/078,291 patent/US20170014390A1/en not_active Abandoned
- 2016-10-07 US US15/288,582 patent/US20170020851A1/en not_active Abandoned
-
2019
- 2019-05-01 US US16/400,844 patent/US11083713B2/en active Active
-
2021
- 2021-07-02 US US17/366,563 patent/US11944607B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130057T1 (hr) | Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom | |
| JP2013231087A5 (hr) | ||
| JP2006504795A5 (hr) | ||
| JP2015038135A5 (hr) | ||
| MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
| HRP20151350T1 (hr) | Neuroprotekcija kod demijelinizacijskih bolesti | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| BRPI0516718A (pt) | forma de dosagem de ibuprofeno de liberação modificada | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2007527914A5 (hr) | ||
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
| IL196425A0 (en) | Pharmaceutical compositions containing ibuprofen and famotidine | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| HRP20150711T1 (hr) | Tretiranje kognitivnih poremeä†aja (r)-7-klor-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| JP2013541583A5 (hr) | ||
| HRP20240309T1 (hr) | Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid | |
| JP2005068010A5 (hr) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2012502915A5 (hr) |